Abstract: The present disclosure provides a system for measuring dynamic physical properties of a rack is configured to simulate various states of a rock, which facilitates the research of the dynamically changing physical properties of the rock. the system including: a kettle (202); a sample clamping device (10) including a lower end rod (103) and a fixed upper end rod (102), and a sample cavity is disposed between the upper end rod (103) and the lower end rod (102) and is located in the kettle (202); an overburden pressure device (400) configured to drive the lower end rod (103) to move up and down; a sample sheath (109) configured to sleeve a sample (101) located in the sample cavity, the sample sheath (109) being contractible inwards under pressure; a confining pressure maintaining device (402) configured to control a pressure in the kettle; and a heater (201) configured to control a temperature in the kettle.

Abstract: An application of a GABAA receptor allosteric enhancer in medicine.

Abstract: A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg/ml-160 mg/ml, the drug being selected from a group consisting of: a local analgesic drug, and the combination of the local analgesic drug and a nonsteroidal analgesic drug and/or an opioid analgesic drug; (2) a drug menstruum in a proportion of 1%-75% (v/v), the menstruum being selected from a group consisting of benzyl alcohol, ethanol, benzyl benzoate, ethyl lactate, and tetrahydrofurfuryl polyethylene glycol ether; and (3) a drug sustained-release formulation having a proportion of 25%-99% (v/v), the sustained-release formulation being selected from a group consisting of natural vegetable oil, synthetic lipid, artificially improved half-natural lipid and derivative thereof. Also disclosed are a preparation process and use of the sustained-release drug delivery system.

Abstract: The present disclosure provides an allosteric enhancing compound of GABAA receptors or a prodrug thereof, a method for preparing the same, and use thereof. The compound is represented by formula (1), wherein R1 and R2 are each independently selected from isopropyl or n-propyl; and when R1 is n-propyl, R2 is not isopropyl.

Abstract: An application of a GABAA receptor allosteric enhancer in medicine.

Abstract: The present invention relates to use of biphenols in the preparation of a medicament for the prevention and treatment of ischemic stroke, specifically to use of 3,3?,5,5?-tetraisopropyl-4,4?-biphenol and salt, ester, or solvate thereof in the preparation of a medicament for the prevention and treatment of ischemic stroke injury.

Abstract: The present invention relates to a biphenyl derivative and use thereof, and the biphenyl derivative has a structure represented by the formula (I) as defined in the specification. The use refers the use of the biphenyl derivative or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the biphenyl derivative or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for the treatment and/or prevention of ischemic stroke.

Abstract: This invention relates to a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol lipid microsphere preparation having 2,2?,6,6?-tetraisopropyl-4,4?-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water.

Abstract: The present invention relates to use of biphenols in the preparation of a medicament for the prevention and treatment of ischemic stroke, specifically to use of 3,3?,5,5?-tetraisopropyl-4,4?-biphenol and salt, ester, or solvate thereof in the preparation of a medicament for the prevention and treatment of ischemic stroke injury.

Abstract: The present invention relates to a biphenyl derivative and use thereof, and the biphenyl derivative has a structure represented by the formula (I) as defined in the specification. The use refers the use of the biphenyl derivative or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the biphenyl derivative or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for the treatment and/or prevention of ischemic stroke.

Abstract: Disclosed is a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol soft capsule composed of a capsule shell and the contents in the capsule, wherein the contents in the capsule include 2,2?,6,6?-tetraisopropyl-4,4?-biphenol, a solvent, and an antioxidant, among others.

Abstract: This invention relates to a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol lipid microsphere preparation having 2,2?,6,6?-tetraisopropyl-4,4?-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water.

Abstract: The present invention provides 3,3?,5,5?-tetraisopropyl-4,4?-diphenol crystal forms I, II and III, and preparation methods thereof. Crystal form I is superior to crystal form II in terms of stability under high temperature, high humidity, strong light and in water medium. The preparation methods for 3,3?,5,5?-tetraisopropyl-4,4?-diphenol crystal forms I, II and III provided in the invention are simple, easy to operate and suitable for industrial production.

Abstract: A non-addictive analgesic sustained-release drug delivery system, comprising: (1) a narcotic analgesic drug having a concentration of 1 mg/ml-160 mg/ml, the drug being selected from a group consisting of: a local analgesic drug, and the combination of the local analgesic drug and a nonsteroidal analgesic drug and/or an opioid analgesic drug; (2) a drug menstruum in a proportion of 1%-75% (v/v), the menstruum being selected from a group consisting of benzyl alcohol, ethanol, benzyl benzoate, ethyl lactate, and tetrahydrofurfuryl polyethylene glycol ether; and (3) a drug sustained-release formulation having a proportion of 25%-99% (v/v), the sustained-release formulation being selected from a group consisting of natural vegetable oil, synthetic lipid, artificially improved half-natural lipid and derivative thereof. Also disclosed are a preparation process and use of the sustained-release drug delivery system.

Abstract: Disclosed is a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol soft capsule composed of a capsule shell and the contents in the capsule, wherein the contents in the capsule include 2,2?,6,6?-tetraisopropyl-4,4?-biphenol, a solvent, and an antioxidant, among others.

Abstract: This invention relates to a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol lipid microsphere preparation having 2,2?,6,6?-tetraisopropyl-4,4?-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water.